ArticleOncotarget2017

Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.

Shayahati Bieerkehazhi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.